Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.

Citation data:

Journal of the American Heart Association, ISSN: 2047-9980, Vol: 7, Issue: 7, Page: 0

Publication Year:
Usage 19
Abstract Views 10
Downloads 9
Citations 2
Citation Indexes 2
Repository URL:;;;
Greenlee, Robert T; Go, Alan S; Peterson, Pamela N; Cassidy-Bushrow, Andrea E; Gaber, Charles; Garcia-Montilla, Romel; Glenn, Karen A; Gupta, Nigel; Gurwitz, Jerry H; Hammill, Stephen C; Hayes, John J; Kadish, Alan; Magid, David J; McManus, David D; Multerer, Deborah; Powers, J David; Reifler, Liza M; Reynolds, Kristi; Schuger, Claudio; Sharma, Param P; Smith, David H; Suits, Mary; Sung, Sue Hee; Varosy, Paul D; Vidaillet, Humberto J; Masoudi, Frederick A Show More Hide
Ovid Technologies (Wolters Kluwer Health); Touro Scholar
Medicine; arrhythmia; implantable cardioverter‚Äźdefibrillator; inappropriate shock; outcomes research; sudden cardiac death; Cardiology; Equipment and Supplies; Cardiovascular Diseases; Clinical Epidemiology; Epidemiology
article description
Primary prevention implantable cardioverter-defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems.